News

The glaucoma toolbox is expanding to include laser, drug delivery systems, and minimally invasive glaucoma surgery.

New World Medical notes that the intuitively designed Streamline features ClickPulse technology that targets the eye’s conventional outflow pathway.

The companies note that the partnership will propel Ray Therapeutics’ lead optogenetics gene therapy to Phase 1-2 clinical trials.

The eye care nonprofit has continually harnessed the power of innovation to reach new heights in the fight against avoidable blindness.

The group is offering free sight-savings resources to employees and their employers.

This novel surgical system could dramatically improve outcomes for patients with glaucoma with its remarkable level of precision that is unachievable during standard glaucoma surgery.

According to the U.S. Department of Health and Human Services, nearly $19 billion in total aid has been distributed to providers since November.

The company expects to have topline proof of concept data by the end of the first quarter of the year.

TearSolutions Inc. is preparing to conduct two trials, one in a primary Sjögren’s Syndrome patient population and the second in a potentially less severe general dry eye population for the treatment of DED.

In a blog, Mackenzie Andrews, the CCO and a co-founder of Nanodropper, discusses the need to update policies on single-use and early disposal of eyedrops.

Cynthia Matossian, MD, FACS, ABES, points out that there has been confusing news lately about what is (and is not) covered by Medicare when it comes to in-office treatments for meibomian gland dysfunction.

The organization uses its Eyes on Capitol Hill program to educate lawmakers and their staff on a variety of vision health issues, including vision health inequities, the need for improved vision surveillance, the impact of community eye health programs, and disparities in access to affordable eyecare services.

Investigators at Trinity College Dublin have highlighted the SARM1 gene, a key driver in the damage that ultimately leads to impaired vision.

Investigators conducted a study of the ocular findings in infants with congenital Zika virus syndrome that showed the findings were similar and occurred frequently among the affected infants.

KSI-301, a therapy for patients with nAMD, did not meet the primary endpoint of showing non-inferior visual acuity gains compared to aflibercept given every eight weeks, however it was safe and well tolerated with no new or unexpected safety signals.

Investigators at the Eye Clinic, Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy, found that the appearance of the retina and optic disc was associated with the SARS-CoV-2 virus.

Study investigators compared 2 novel lens designs using data obtained from 19 investigational sites in Australia, Canada, Spain, and the UK

The company will use proceeds from the Series A to assemble and develop a diversified pipeline of product candidates that combines scientifically compelling targets with innovative translational approaches.

The company is revealing the 8-year follow up results of its novel Elios Excimer Laser Trabeculostomy procedure combined with cataract surgery.

While there is currently no cure for blindness, an artificial vision system has undergone its first successful implantation, bringing with it the potential to restore partial vision to people who have lost their sight.

The NGF0121 study will enroll 100 patients and will use Schirmer's test and the Symptom Assessment Questionnaire in Dry Eye questionnaire as its co-primary endpoints to measure improvement in signs and symptoms of dry eye over time.

A pair of Japanese ophthalmologists have concluded that SARS-CoV-2 may target lacrimal gland tissue and manifest as chronic inflammation.

Results from the study were presented by Russell Tait, PhD, CEO of PolyActiva, at the Glaucoma 360 New Horizons Forum in San Francisco, California

Tiffani Martin was diagnosed with type 1 juvenile diabetes when she was just 5 years old, and has battled myriad health issues as a result, including vision loss. Leading the charge for a multifactorial approach to combat diabetes, Kristen Nwanyanwu, MD, MBA, MHS, and her team have embraced the need for a multi-pronged program to address health disparities in diabetic retinopathy.

Utilizing new technology, surgeons can be 20 to 40 times more precise.

Proper measurement of the eye is key to predicting lens strength.